A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression (NCT07546500)
A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.
Who can join: Review the eligibility criteria below.
Location: Site 0107 — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (59 Sites)
Showing the first 25 of 59 sites.
- Site 0107 — Phoenix, Arizona
- Site 0110 — Antioch, California
- Site 0104 — Beverly Hills, California
- Site 0115 — San Francisco, California
- Site 0101 — Torrance, California
- Site 0111 — Camden, New Jersey
- Site 0108 — Columbus, Ohio
- Site 0105 — Portland, Oregon
- Site 0109 — Philadelphia, Pennsylvania
- Site 0113 — Philadelphia, Pennsylvania
- Site 0114 — Willow Grove, Pennsylvania
- Site 0112 — Sioux Falls, South Dakota
- Site 1101 — Randwick, New South Wales
- Site 1102 — Adelaide, South Australia
- Site 1103 — Nedlands,
- Site 3002 — Brussels,
- Site 3001 — Leuven,
- Site 0201 — Toronto, Ontario
- Site 0204 — Montreal, Quebec
- Site 0203 — Montreal, Quebec
- Site 0202 — Sherbrooke, Quebec
- Site 3508 — Besançon,
- Site 3502 — Brest,
- Site 3507 — Dijon,
- Site 3504 — Lyon,
📞 Contact the Study Coordinator
Phone: (858) 263-4333
Email: medicalaffairs@zentalis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
- Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
- NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.